他汀序贯治疗对急性冠脉综合征患者血脂及高敏C反应蛋白的影响

目的：探讨阿托伐他汀序贯治疗对急性冠脉综合征（ACS）患者血脂及高敏C反应蛋白（hsCRP）的影响。方法：ACS患者107例，随机分为常规治疗组（50例）和观察组（57例），疗程为4周。治疗前、后查血脂及hsCRP水平。结果：治疗后两组血清hsCRP、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白一胆固醇（LDL-C）水平均较治疗前明显下降，高密度脂蛋白一胆固醇（HDL-C）水平较治疗前明显升高（P均〈0．05）；与常规治疗组治疗后比较，观察组治疗后hsCRP（7．85±4．91）mg／L比（5．99±3．23）mg／L]、TC（4．86±0．95）mmol／L比（4．39±0．81）mmol／L]，LDL—C（2．47±0．77）mmol／L比（2．12±0．68）mmol／L]水平明显降低（P均〈0．05）。结论：改良他汀序贯治疗对调脂及降低超敏C反应蛋白的作用较常规治疗更显著。

Influence of sequential therapy of atorvastatin on levels of high sensitive C-reactive protein and blood lipids in patients with acute coronary syndrome

Objective： To investigate effects of sequential therapy of atorvastatin on levels of high sensitive C-reactive protein （hsCRP） and blood lipids in patients with acute coronary syndrome （ACS）. Methods： A total of 107 ACS pa- tients were randomly divided into routine treatment group （n=50） and observation group （n=57） , course of treat- ment was four weeks. Levels of hsCRP and blood lipids were examined before and after treatment. Results： After treatment, levels of serum hsCRP, total cholesterol （TC）, triglyceride （TG） and low density lipoprotein-cholesterol （LDL-C） significantly decreased, and level of high density lipoprotein-cholesterol （HDL-C） significantly increased in the two groups compared with before treatment （P〈0.05 all）, compared with routine treatment group, levels of hsCRP （7.85±4.91） mg/L vs. （5.99±3.23） mg/L], TC ]4.86±0.95） mmol/L vs. （4.39±0.81） mmol/L] and LDL-C （2.47±0.77） mmol/L vs. （2.12±0.68） mmol/L] significantly decreased in observation group after treatment （P〈0.05 all）. Conclusion： Improved sequential therapy of atorvastatin possesses more obvious effects on regulation of lipids and lowering level of hs-CRP.